Lynn Seely, Myovant CEO (Myovant)
In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer
Myovant Sciences $MYOV won’t be getting coal in their stocking this Christmas.
The Swiss biotech, formerly part of the Vivek Ramaswamy family of Vants, won FDA approval of its relugolix drug on Friday afternoon for the treatment of advanced prostate cancer. It’s the first oral hormone therapy approved for the indication, regulators said, and the drug will be marketed as Orgovyx. PDUFA action had been scheduled for Dec. 20.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters